MONTREAL, QUEBEC -- (MARKET WIRE) -- October 26, 2006 -- Ambrilia Biopharma Inc. (TSX: AMB), a biopharmaceutical company developing innovative therapeutics in the fields of oncology and infectious diseases, announced today positive results of a pivotal pharmacokinetic (PK) study of its lead specialty generic, Octreotide, for the treatment of acromegaly.
